96 related articles for article (PubMed ID: 25175149)
1. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Kim S; Jeon M; Lee J; Han J; Oh SJ; Jung T; Nam SJ; Kil WH; Lee JE
Oncol Rep; 2014 Nov; 32(5):2230-6. PubMed ID: 25175149
[TBL] [Abstract][Full Text] [Related]
2. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.
Kim S; Han J; Jeon M; You D; Lee J; Kim HJ; Bae S; Nam SJ; Lee JE
Tumour Biol; 2016 Aug; 37(8):11397-407. PubMed ID: 26984157
[TBL] [Abstract][Full Text] [Related]
3. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
5. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.
Kim S; Han J; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
Anticancer Res; 2011 Nov; 31(11):3767-73. PubMed ID: 22110198
[TBL] [Abstract][Full Text] [Related]
6. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
[TBL] [Abstract][Full Text] [Related]
7. Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells.
Jeon M; Lee J; Nam SJ; Shin I; Lee JE; Kim S
Exp Cell Res; 2015 Apr; 333(1):116-26. PubMed ID: 25743092
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
9. Silibinin induces cell death through reactive oxygen species-dependent downregulation of notch-1/ERK/Akt signaling in human breast cancer cells.
Kim TH; Woo JS; Kim YK; Kim KH
J Pharmacol Exp Ther; 2014 May; 349(2):268-78. PubMed ID: 24472723
[TBL] [Abstract][Full Text] [Related]
10. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
11. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway.
Tsai PC; Hsieh CY; Chiu CC; Wang CK; Chang LS; Lin SR
Toxicon; 2012 Oct; 60(5):734-43. PubMed ID: 22683533
[TBL] [Abstract][Full Text] [Related]
13. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
[TBL] [Abstract][Full Text] [Related]
14. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
15. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
Bosch-Barrera J; Menendez JA
Cancer Treat Rev; 2015 Jun; 41(6):540-6. PubMed ID: 25944486
[TBL] [Abstract][Full Text] [Related]
16. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells.
Kim S; Kil WH; Lee J; Oh SJ; Han J; Jeon M; Jung T; Lee SK; Bae SY; Lee HC; Lee JH; Yi HW; Kim SW; Nam SJ; Lee JE
Oncol Rep; 2014 Dec; 32(6):2666-72. PubMed ID: 25269647
[TBL] [Abstract][Full Text] [Related]
17. Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.
Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
Phytomedicine; 2009 Jun; 16(6-7):573-80. PubMed ID: 19181503
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
19. Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer.
Yotsumoto F; Tokunaga E; Oki E; Maehara Y; Yamada H; Nakajima K; Nam SO; Miyata K; Koyanagi M; Doi K; Shirasawa S; Kuroki M; Miyamoto S
Mol Cancer Res; 2013 May; 11(5):506-17. PubMed ID: 23443317
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
